
News|Articles|December 10, 2012
FDA expands Zytiga's use for late-stage prostate cancer
FDA expanded the approved use of abiraterone acetate (Zytiga, Jannsen Bioech) to treat men with late-stage castration-resistant prostate cancer prior to receiving chemotherapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Overlooked bladder nerves now thought to reduce UTI burden through pain signaling, study shows
2
Real-World Usage of Biologics in Psoriatic Arthritis
3
Medicare beneficiaries are paying more for price-negotiated drugs, survey finds
4
Researchers discover new pathway to fight liver inflammation
5





















